ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Clinical trials for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for AML patients: targeted drug ziftomenib enters final testing phase
Disease control Recruiting nowThis large Phase 3 trial is testing whether adding the experimental drug ziftomenib to standard chemotherapy helps people with untreated acute myeloid leukemia (AML) who have specific genetic mutations. About 1,300 participants will be randomly assigned to receive either ziftomen…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE3 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy aims to improve AML treatment for patients with specific gene changes
Disease control Recruiting nowThis early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising new combo targets hard-to-treat leukemia mutations
Disease control Recruiting nowThis study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy targets Hard-to-Cure leukemia
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill could boost leukemia treatment for patients with specific gene changes
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC